SUBSCRIPTION AGREEMENTSubscription Agreement • November 21st, 2022 • Biodesix Inc • Services-medical laboratories • Delaware
This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is entered into this 21st day of November, 2022, by and between Biodesix, Inc., a Delaware corporation (the “Issuer”), and the undersigned (“Subscriber” or “you”).
Security Agreement Dated as of November 21, 2022 among Biodesix, Inc., as Grantor, The Other Grantors from Time to Time Party hereto and Perceptive Credit Holdings IV, LP, as Administrative AgentSecurity Agreement • November 21st, 2022 • Biodesix Inc • Services-medical laboratories • New York
This Security Agreement (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), dated as of November 21, 2022, is made by and among Biodesix, Inc., a Delaware corporation (“Borrower” and collectively with each entity that becomes a “Grantor” hereunder as contemplated by Section 5.12, each, a “Grantor”, and collectively, the “Grantors”), and Perceptive Credit Holdings IV, LP, a Delaware limited partnership, as administrative agent (in such capacity, the “Administrative Agent”) for the Secured Parties.
Credit Agreement and Guaranty dated as of November 16, 2022 among Biodesix, Inc., as the Borrower, The Guarantors from Time to Time Party hereto, as Guarantors, The Lenders from Time to Time Party hereto, as Lenders, and Perceptive Credit Holdings IV,...Credit Agreement • November 21st, 2022 • Biodesix Inc • Services-medical laboratories • New York
Credit Agreement And Guaranty, dated as of November 16, 2022 (this “Agreement”), among Biodesix, Inc., a Delaware corporation (the “Borrower”), certain Guarantors from time to time parties hereto, the lenders from time to time party hereto (each, as a “Lender” and collectively, the “Lenders”) and Perceptive Credit Holdings IV, LP, a Delaware limited partnership (“Perceptive”), as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”).
30,500,000 Shares BIODESIX, INC. COMMON STOCK (PAR VALUE $0.001 PER SHARE) UNDERWRITING AGREEMENTBiodesix Inc • November 21st, 2022 • Services-medical laboratories • New York
Biodesix, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom William Blair & Company, L.L.C. is acting as representative (the “Representative”), 30,500,000 shares of its Common Stock, $0.001 par value per share (the “Firm Shares”). The Company also proposes to issue and sell to the several Underwriters not more than an additional 4,575,000 shares of its Common Stock, $0.001 par value per share (the “Additional Shares”), if and to the extent that the Representative shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “Shares.” The shares of Common Stock, $0.001 par value per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter
